Home Neoplasma 2020 Neoplasma Vol.67, No.3, p.650–659, 2020

Journal info


6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.67, No.3, p.650–659, 2020

Title: Blastic plasmacytoid dendritic cell neoplasm: First retrospective study in the Czech Republic
Author: M. CERNAN, T. SZOTKOWSKI, M. HISEMOVA, P. CETKOVSKY, L. SRAMKOVA, J. STARY, Z. RACIL, J. MAYER, J. SRAMEK, P. JINDRA, B. VISEK, P. ZAK, J. NOVAK, T. KOZAK, T. FURST, T. PAPAJIK

Abstract: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with aggressive behavior and poor prognosis. We present the first retrospective analysis mapping its incidence and therapeutic outcomes in patients diagnosed and treated from 2000 to 2017 in the Czech Republic. The cohort comprised 14 patients (10 males, 4 females) with a median age at diagnosis of 39 years (range, 5-68 years). Initially, skin involvement was noted in 10 (71%) patients and bone marrow infiltration was present in 9 (64%). The first complete remission was achieved in 6/14 (43%) patients after acute lymphoblastic leukemia/lymphoma induction therapy and in 3/14 (21%) patients after acute myeloid leukemia regimen. Nine patients underwent allogeneic hematopoietic cell transplantation, with two patients achieving the first complete remission only after allogeneic transplantation. Patients undergoing allogeneic hematopoietic cell transplantation had longer overall survival than those treated without transplantation (the median survival over the period 16.4 vs. 8.1 months). Relapse of the disease was a significant predictor of mortality (p=0.05). Over the study period, patients’ survival ranged from 3.3 to 44.2 months, with a median overall survival of 13 months. Our results revealed an effectivity of allogeneic hematopoietic cell transplantation on complete remission achievement in refractory/relapsed disease. The study aimed to present the actual data from the Czech Republic and thus contribute to a global understanding of BPDCN.

Keywords: blastic plasmacytoid dendritic cell neoplasm, BPDCN, allogeneic hematopoietic cell transplantation, SL-401
Published online: 15-May-2020
Year: 2020, Volume: 67, Issue: 3 Page From: 650, Page To: 659
doi:10.4149/neo_2020_190507N407
Price: 24.00 €






© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.